According to Dr. Bertha Madras, deputy director of demand reduction in the White House Office of National Drug Control Policy under President George W. Bush, random drug testing gives young people a good reason not to succumb to peer pressure. But the implementation of random drug testing in schools has stirred a controversial public health debate. Is this an invasion of privacy? Is school an appropriate environment for these measures? Dr. Madras provides a detailed explanation of current policy, and responds to critical comments from groups that oppose the widespread implementation of random drug testing in schools. Dr. Bill Rutenberg hosts.
Random Drug Testing in Schools
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Overview
According to Dr. Bertha Madras, deputy director of demand reduction in the White House Office of National Drug Control Policy under President George W. Bush, random drug testing gives young people a good reason not to succumb to peer pressure. But the implementation of random drug testing in schools has stirred a controversial public health debate. Is this an invasion of privacy? Is school an appropriate environment for these measures? Dr. Madras provides a detailed explanation of current policy, and responds to critical comments from groups that oppose the widespread implementation of random drug testing in schools. Dr. Bill Rutenberg hosts.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
Phase 3 study results of plozasiran in patients with FCS
Evolutions in Duchenne Muscular Dystrophy: Treatment Implications for the Present and Future
IgG4-RD Case Conversations: Retroperitoneal Fibrosis with Refractory Ureteral Involvement
Episode 2 Part B: Effectively Transferring Over the CKD Patient at the Right Time
HF Management for Patients with Comorbid Conditions
Analysis of Patients With and Without AF Living With HFmrEF/HFpEF: FINEARTS-HF
Mode of Death in Patients With HFmrEF/HFpEF: The FINEARTS-HF Trial
Semaglutide improves walking distance, symptoms and QoL in patients with PAD and T2D
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?